Skip to main content
Premium Trial:

Request an Annual Quote

Roche Moves Wisconsin-Based RNA Rx Group to New Facility

Premium

Roche this week said that it has officially moved its Madison, Wisc.-based unit, which is part of the company's RNA therapeutics group, to a new facility located within the University of Wisconsin Research Park.

The unit, called Roche Madison, was created through Roche's $125 million cash acquisition of Mirus Bio (see RNAi News, 7/24/2008). The transaction, which was designed to bolster Roche's RNA drug-delivery capabilities, included Mirus' polymer-based dynamic polyconjugate siRNA- delivery technology.

According to Roche, the new Roche Madison site currently has 45 staffers. The company said it plans to make additional hires over the next six to twelve months.

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.